About this trial

The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.

Eligibility criteria

Qualifiers

Diagnosis of ATTR-CM according to current diagnostic criteria

Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR/TR) parameters, performed within ±6 months of diagnosis

Age ≥ 18 years

Willingness to participate in the study and provide informed consent

Disqualifiers

Severe aortic valve disease requiring intervention

Inability to provide informed consent or participate in study follow-up

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

8
Austria
Medical University of Graz8010, GrazStyria, Austria
Department of Internal Medicine II, Medical University of Vienna1090, Vienna Austria
Germany
Medizinische Klinik und Poliklinik I, Klinikum der Universitaet Muenchen, Ludwig-Maximilians-University81377, MunichBavaria, Germany
Department of Cardiology, University Hospital Frankfurt, Goethe University60596, Frankfurt am MainHesse, Germany

Sponsors and collaborators

Medical University of Vienna

Lead sponsor